Location History:
- Carlsbad, CA (US) (2002)
- San Diego, CA (US) (2003)
Company Filing History:
Years Active: 2002-2003
Title: The Innovative Contributions of Margaret Galvin in Genetic Research
Introduction
Margaret Galvin, an accomplished inventor based in San Diego, CA, has made significant strides in the field of genetic research. With a total of two patents to her name, she has focused her work on understanding genetic polymorphisms and their implications for drug metabolism. Her contributions are pivotal in enhancing patient care and developing models for drug testing.
Latest Patents
Margaret's latest patents include groundbreaking work on the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene and the human UDP-glucuronosyltransferase 1 (UGT1) gene. The first patent identifies genetic polymorphisms in the UGT2B4, UGT2B7, and UGT2B15 genes that affect UGT2B activity. This research utilizes nucleic acids containing these polymorphic sequences to screen patients for altered metabolism associated with UGT2B substrates. This has implications for potential drug-drug interactions, adverse effects, and diseases linked to environmental or occupational toxins. Additionally, the nucleic acids are employed to establish animal, cell, and in vitro models for studying drug metabolism. The second patent similarly focuses on the UGT1 gene, where the identified polymorphisms alter UGT1-dependent drug metabolism, again utilizing nucleic acids to mitigate drug-related complications in patients.
Career Highlights
Margaret Galvin's work at Dna Sciences Laboratories, Inc. positions her at the forefront of genetic research. Her innovative approach to understanding the intricacies of human metabolism through genetic analysis has garnered her recognition in the scientific community. The impact of her patents is felt in both the research laboratory and clinical settings, where her work aids in the prediction and management of drug responses in patients.
Collaborations
Throughout her career, Margaret has collaborated with esteemed colleagues, including Laura Penny and Andrew Miller. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the research output. Their combined efforts in genetic studies contribute to the broader understanding of drug metabolism and toxicity.
Conclusion
In conclusion, Margaret Galvin stands out as a significant contributor to the field of genetic research, particularly in the realm of drug metabolism. With her two innovative patents, she has paved the way for advancements in patient screening and treatment, helping to mitigate risks associated with drug interactions. As her work continues to evolve, Margaret's contributions are sure to leave a lasting legacy in the field of genetics.